// App-Quantinova.ai

e21008 : Correlation of survival of NSCLC patients given nivolumab with treatment related-eosinophilia, autoimmunity and previous bevacizumab containing regimens.

Researchers

Presenter

  • Rocco Giannicola

Principal Investigators

  • Graziella D'arrigo

  • Pierpaolo Pastina

  • Michele Caraglia

  • Valerio Nardone

  • Cirino Botta

  • Vito Barbieri

  • Pierfrancesco Tassone

  • Gabriella Misso

  • Silvia Zappavigna

  • Marika Monoriti

  • Gaetana Porto

  • Giovanni Tripepi

  • Pierosandro Tagliaferri

  • Luigi Pirtoli

  • Antonia Consuelo Falzea

  • Pierpaolo Correale

Medical Centers

  • National Council of Research (CNR), Grand Metropolitan BMM Hospital, Reggio Calabria, Italy

  • Radiation Oncology Unit, Siena University Hospital, Siena, Italy

  • Department of Biochemistry, Biophisics and General Pathology, University of Campania "L.Vanvitelli", Caserta, Italy

  • Unit of Medical Oncology, AUO MaterDomini, Magna Graecia University, Catanzaro, Italy, Catanzaro, Italy

  • Medical Oncology Unit, Campus Salvatore Venuta, Magna Grcia University and Tommaso Campanella Cancer Center, Catanzaro, Italy

  • Unit of Medical Oncology, AUO MaterDomini, Magna Graecia University, Catanzaro, Italy, Catanzaro, Italy

  • Department of Biochemistry, Biophisics and General Pathology, University of Campania "L.Vanvitelli", Caserta, Italy

  • Department of Biochemistry, Biophisics and General Pathology, University of Campania "L.Vanvitelli", Caserta, Italy

  • Laboratory of Autoimmunity, Grand Metropolitan BMM Hospital, Reggio Calabria, Italy

  • Section of Medical Oncology, University of Catanzaro School of Medicine, Catanzaro, Italy

  • Istituto Toscano Tumori, Florence, Italy

  • Unit of Radiation Oncology, University Hospital of Siena, Siena, Italy

  • Unit of Medical Oncology, Grand Metropolitan BMM Hospital, Reggio Calabria, Italy

  • Unit of Medical Oncology, Grand Metropolitan BMM Hospital, Reggio Calabria, Italy

Locations

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • T helper 2

  • Type 1 T helper

Drug/Treatment

  • Bevacizumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved